ECKERT & ZIEGLER BG 
By Regulated information
First Quarter 2013 Interim Statement
Seneffe - Belgium, May 3, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its Interim Statement for the first quarter 2013.
The Interim Statement report including the milestones of the 1st quarter 2013 and a selection of consolidated key figures for the 3 months ending March 31, 2013 can be downloaded at:
www.bebig.eu > Investor Relations > Financial Reports
Sales for the 1st quarter 2013 reached 5.5 million EUR, compared to 7.2 million EUR in 1st quarter 2012, showing a decrease of 23.8%. The main components were income generated by the sales of permanent brachytherapy I-125 (Iodine-125) radiotherapeutic implants as well as income from temporary brachytherapy equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium-192) sources (also called "afterloaders").
Earnings before interest and taxes (EBIT) have reached 1.0 million EUR in the 1st quarter 2013, versus 0.5 million EUR in the 1st quarter 2012, showing an increase of 79.6%.
Net profit reached 0.6 million EUR in the 1st quarter 2013, compared to the net profit of 0.1 million EUR in the 1st quarter 2012.
Total equity of the group stood at 43.6 million EUR on March 31, 2013, versus 42.9 million EUR in December 31, 2012.
Cash amounted to 2.3 million EUR at the end of March 2013, versus 3.3 million EUR in December 2012. The equity to assets ratio stood at 72.8% end of March 2013.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, as well as in India and in Brazil. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).
Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
